Pacific Biometrics, Inc., Announces Appointment of Vice President for Business Development and Sales & Marketing

Business Wire, July 23, 2007

SEATTLE -- Pacific Biometrics, Inc. ("PBI") (OTCBB:PBME), announces the appointment of Richard J. Gordon, M.S., as its new Vice President of Business Development and Sales & Marketing. Mr. Gordon joins PBI from Molecular Devices (a division of MDS Analytical Technologies) in Sunnyvale, CA, where he was Technical Sales Representative (Pacific Northwest and Western Canada). Mr. Gordon will be responsible for overseeing all of the company's business development and sales & marketing activities, including all East Coast pharmaceutical accounts, as well as developing the overall business development and marketing strategy for PBI.

Ron Helm, Chief Executive Officer of Pacific Biometrics, commented, "We are absolutely delighted that Rick has joined PBI. Rick has a stellar record of achievement in sales, consistently exceeding sales targets and achieving an average of 30% year-over-year sales growth during the period 2004-2007. At Molecular Devices, Rick was recognized as both the Worldwide Sales Leader and the North American Life Science Sales Leader, and is the record holder for earliest to meet annual sales quotas. Rick has a deep understanding of the life sciences industry, particularly in the areas of drug discovery and development. He is an excellent fit with our strong science-driven approach and culture of quality and excellence. Rick will be an integral part of PBI's continuing drive to build and enhance market penetration in the provision of specialty central laboratory services. He will supervise the entire business development group at PBI, manage our key East Coast accounts, and lead the development of expanded sales and marketing activities."

Helm continued, "We are very encouraged by our recent successes in signing significant new contracts for specialty testing, and with Rick joining the company we look forward to building on this foundation and substantially growing our backlog in both traditional and new areas."

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and, through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements, including, but not limited to, the amount of revenues that we may receive under this contract, the duration, size and scope of this contract, our strategic planning and business development plans, impacts on our financial results, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2006, and our Form 10-QSB for the quarters ended September 30, 2006, December 31, 2006, and March 31, 2007).